Correlations Between Cerebrospinal Fluid Biomarkers Concentration and Severity of Cognitive Impairment in Alzheimer Disease
DOI:
https://doi.org/10.15225/PNN.2018.7.4.3Keywords
Tau, pTau, Alzheimer's disease, Mini Mental State Examination, cognitive impairmentAbstract
Introduction. Alzheimer’s disease (AD) is a progressive, neurodegenerative disease and the most common cause of dementia.
Aim. The aim of the study was to assess the concentration of the 42 amino acid isoform of Aβ (Aβ1-42), Aβ1-42/Aβ1-40 (42 amino acid isoform of Aβ/40 amino acid isoform of Aβ) ratio, Tau and hyperphosphorylated Tau (pTau) protein in cerebrospinal fluid (CSF) of patients diagnosed with Alzheimer disease (AD) and to compare their correlations with degree of cognitive impairment assessed with Mini Mental State Examination (MMSE).
Material and Methods. In this study, using the ELISA immunoassay standard kits, we measured the average concentration of Aβ1-42, Aβ1-42/Aβ1-40 ratio, Tau and pTau protein, in the CSF obtained from subjects diagnosed with Alzheimer’s disease (n=20, 13 women and 7 men, mean age 69.9±10.4). The cognitive functions of the patients were assessed with MMSE test. The correlations between concentration of CSF biomarkers and degree of cognitive impairment were measured using nonparametric Spearman rank correlation coefficient.
Results. Our results showed negative correlation between concentration of Tau protein in CSF and the number of points scored in MMSE test (r=-0.45; p=0.046). There was no correlation between a degree of cognitive impairment assessed with MMSE test and concentration of pTau (r=-0.42; p=0.066), Aβ1-42 (r=0.02; p=0.927), and Aβ1-42/Aβ1-40 ratio (r=-0.07; p=0.775). There was also positive correlation between concentration of Aβ1-42 and Aβ1-42/Aβ1-40 ratio (r=0.91; p<0.0001), and between concentration of Tau and pTau (r=0.94; p<0.0001).
Conclusions. Tau protein plays not only a crucial role in the early diagnostics, but also reflects the intensity of cognitive impairment in course of Alzheimer disease. (JNNN 2018;7(4):150–154)
References
Burns A., Iliffe S. Alzheimer’s disease. BMJ. 2009;338:b158.
Wallin A.K., Blennow K., Andreasen N., Minthon L. CSF biomarkers for Alzheimer’s Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord. 2006;21(3):131–138.
Bouwman F.H., van der Flier W.M., Schoonenboom N.S. et al. Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology. 2007;69(10):1006–1011.
Wahlund L.O., Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett. 2003;339(2):99–102.
Blomberg M., Jensen M., Basun H., Lannfelt L., Wahlund L.O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett. 1996;214(2–3):163–166.
Andersson C., Blennow K., Almkvist O. et al. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging. 2008;29(10):1466–1473.
Sunderland T., Wolozin B., Galasko D. et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46(6):750–755.
Mollenhauer B., Bibl M., Trenkwalder C. et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease. J Neural Transm (Vienna). 2005;112(7):933–948.
Brys M., Pirraglia E., Rich K. et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30(5):682–690.
Stomrud E., Hansson O., Zetterberg H., Blennow K., Minthon L., Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67(2):217–223.
de Leon M.J., DeSanti S., Zinkowski R. et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging. 2006;27(3):394–401.
Sluimer J.D., Bouwman F.H., Vrenken H. et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging. 2010;31(5):758–764.
Andreasen N., Vanmechelen E., Van de Voorde A. et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol Neurosurg Psychiatry. 1998;64(3):298–305.
Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131–144.
Price J.L., Morris J.C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol. 1999;45(3):358–368.
Dubois B., Feldman H.H., Jacova C. et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–746.
Pangman V.C., Sloan J., Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. Appl Nurs Res. 2000;13(4):209–213.
Tuijl J.P., Scholte E.M., de Craen A.J., van der Mast R.C. Screening for cognitive impairment in older general hospital patients: comparison of the Six-Item Cognitive Impairment Test with the Mini-Mental State Examination. Int J Geriatr Psychiatry. 2012;27(7):755–762.
Jack C.R. Jr, Knopman D.S., Jagust W.J. et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–128.
Miller D.L., Papayannopoulos I.A., Styles J. et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch Biochem Biophys. 1993;301(1):41–52.
Roher A.E., Palmer K.C., Yurewicz E.C., Ball M.J., Greenberg B.D. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. J Neurochem. 1993;61(5):1916–1926.
Iqbal K., Grundke-Iqbal I., Zaidi T. et al. Defective brain microtubule assembly in Alzheimer’s disease. Lancet. 1986;2(8504):421–426.
Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913–4917.
Blennow K., Vanmechelen E., Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol. 2001;24(1–3):87–97.
Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234.
Herukka S.K., Hallikainen M., Soininen H., Pirttilä T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294–1297.
Seppälä T.T., Koivisto A.M., Hartikainen P., Helisalmi S., Soininen H., Herukka S.K. Longitudinal changes of CSF biomarkers in Alzheimer’s disease. J Alzheimers Dis. 2011;25(4):583–594.
Vemuri P., Wiste H.J., Weigand S.D. et al. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75(2):143–151.
Braak H., Braak E., Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993;33(6):403–408.
Josephs K.A., Whitwell J.L., Ahmed Z. et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63(2):204–212.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 245
Number of citations: 0